Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 143

recruiting
3 982
countries
28
conditions
2 106

2 730 trials match your criteria

Parkinson's disease

Not recruiting

Study on the Effects and Safety of Prasinezumab for Patients with Early Parkinson's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab

Neoplasm

Not recruiting

Study of RVU120 for Patients with Advanced Solid Tumors After Standard Treatments Have Failed

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride

Porphyria non-acute

Not recruiting

Study on the Safety and Tolerability of Oral Dersimelagon for Patients with Erythropoietic Protoporphyria or X-Linked Protoporphyria

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dersimelagon Phosphate

Study Comparing Lazertinib and Subcutaneous Amivantamab with Intravenous Amivantamab for Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Diabetic neuropathy

Not recruiting

Study on Medical Cannabis Aerosol for Treating Diabetic Nerve Pain in Patients Using Syqe Inhaler

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cannabis Sativa Flower

Prostate cancer

Not recruiting

Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide

Neoplasm

Not recruiting

Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Repotrectinib

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ofatumumab

Study of Atezolizumab and Tiragolumab for Patients with Unresectable Esophageal Squamous Cell Carcinoma After Chemoradiotherapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study on the Effects of Casimersen and Golodirsen for Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Casimersen

Myasthenia gravis

Not recruiting

Study on the Safety and Tolerability of DNTH103 for Adults with Generalized Myasthenia Gravis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103

Study of Amivantamab and Cetrelimab for Patients with Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.